Alexion Pharmaceuticals - ALXN Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: -100.00%
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$182.50 As of 07/28/2021 01:00 AM ET

+0 (0.00%)

Get New Alexion Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ALXN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALXN

^$0.00

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for Alexion Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $182.50.

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Alexion Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/31/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/29/2023

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/29/2023

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/28/2023

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/26/2023

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/24/2024

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/24/2024

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/23/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/5/2021	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$205.00	Low
5/3/2021	SVB Leerink	Boost Target	Market Perform	$156.00 ➝ $173.00	Medium
4/26/2021	Credit Suisse Group	Initiated Coverage	Neutral	$190.00	Low
3/29/2021	SVB Leerink	Reiterated Rating	Outperform ➝ Market Perform	$196.00 ➝ $156.00	N/A
3/23/2021	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$196.00 ➝ $156.00	Medium
2/5/2021	SVB Leerink	Lower Target	Outperform	$200.00 ➝ $196.00	Medium
2/4/2021	Piper Sandler	Downgrade	Overweight ➝ Neutral		Low
1/8/2021	Raymond James	Downgrade	Outperform ➝ Market Perform		Low
12/16/2020	Truist Financial	Downgrade	Buy ➝ Hold	$155.00 ➝ $175.00	Medium
12/15/2020	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral	$175.00	Low
12/15/2020	Roth Capital	Boost Target		$50.00 ➝ $73.00	Low
12/14/2020	SVB Leerink	Boost Target	Outperform	$159.00 ➝ $200.00	High
12/14/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$140.00 ➝ $175.00	High
12/14/2020	Wedbush	Downgrade	Outperform ➝ Neutral	$175.00	High
12/14/2020	Royal Bank of Canada	Boost Target	Outperform	$139.00 ➝ $175.00	High
12/14/2020	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$152.00 ➝ $175.00	High
12/14/2020	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$147.00 ➝ $194.00	High
11/19/2020	Sanford C. Bernstein	Initiated Coverage	Market Perform	$148.00	Low
11/5/2020	Smith Barney Citigroup	Boost Target		$145.00 ➝ $157.00	Low
11/5/2020	Royal Bank of Canada	Reiterated Rating	Buy		Medium
10/30/2020	SVB Leerink	Boost Target	Outperform	$159.00 ➝ $163.00	Medium
10/30/2020	Morgan Stanley	Lower Target	Equal Weight	$121.00 ➝ $119.00	Medium
10/29/2020	Piper Sandler	Boost Target	Overweight	$175.00 ➝ $179.00	Medium
10/28/2020	UBS Group	Initiated Coverage	Neutral	$133.00	High
10/13/2020	Morgan Stanley	Boost Target	Equal Weight	$120.00 ➝ $121.00	Low
10/7/2020	Royal Bank of Canada	Boost Target	Outperform	$136.00 ➝ $139.00	High
10/7/2020	William Blair	Reiterated Rating	Hold		High
10/6/2020	Wedbush	Reiterated Rating	Outperform	$156.00	Low
9/1/2020	Stifel Nicolaus	Lower Target	Hold	$120.00 ➝ $117.00	Low
7/31/2020	Raymond James	Lower Target	Outperform	$156.00 ➝ $151.00	Low
7/31/2020	SunTrust Banks	Boost Target	Outperform ➝ Buy	$135.00 ➝ $155.00	Medium
7/31/2020	SVB Leerink	Boost Target	Outperform	$159.00 ➝ $163.00	Medium
7/30/2020	William Blair	Downgrade	Outperform ➝ Market Perform		High
7/30/2020	Oppenheimer	Reiterated Rating	Hold		Medium
6/1/2020	Wedbush	Boost Target	Outperform	$120.00 ➝ $138.00	Low
6/1/2020	Credit Suisse Group	Boost Target	Outperform	$142.00 ➝ $147.00	Low
5/29/2020	SVB Leerink	Boost Target	Outperform	$150.00 ➝ $159.00	High
5/26/2020	Credit Suisse Group	Initiated Coverage	Buy	$142.00	High
5/8/2020	SunTrust Banks	Lower Target	Buy	$141.00 ➝ $135.00	Low
5/7/2020	BMO Capital Markets	Lower Target	Outperform	$147.00 ➝ $142.00	Low
5/7/2020	SVB Leerink	Lower Target	Outperform	$156.00 ➝ $150.00	Low
5/7/2020	Raymond James	Lower Target	Outperform	$159.00 ➝ $156.00	Low
5/7/2020	Morgan Stanley	Boost Target	Equal Weight	$116.00 ➝ $120.00	Low
5/6/2020	Cfra	Lower Target	Strong-Buy	$165.00 ➝ $159.00	Medium
5/6/2020	Nomura	Reiterated Rating	Buy	$133.00	Medium
5/5/2020	William Blair	Downgrade	Outperform ➝ Market Perform		Medium
4/27/2020	Cantor Fitzgerald	Initiated Coverage	Neutral	$121.00	High
4/20/2020	UBS Group	Reiterated Rating	Reduce		High
4/17/2020	JPMorgan Chase & Co.	Lower Target	Overweight	$168.00 ➝ $163.00	High
4/15/2020	Morgan Stanley	Lower Target	Equal Weight	$127.00 ➝ $116.00	Low
3/17/2020	Oppenheimer	Downgrade	Outperform ➝ Market Perform		High
3/12/2020	Wolfe Research	Initiated Coverage	Outperform	$140.00	High
3/5/2020	Bank of America	Downgrade	Buy ➝ Neutral	$130.00 ➝ $110.00	Low
2/25/2020	SunTrust Banks	Reiterated Rating	Buy	$141.00	Medium
2/3/2020	Nomura Securities	Lower Target	Buy	$165.00 ➝ $133.00	Low
1/31/2020	Robert W. Baird	Lower Target	Outperform	$165.00 ➝ $140.00	High
1/31/2020	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Positive	$135.00	Medium
1/31/2020	Raymond James	Lower Target	Outperform	$162.00 ➝ $159.00	Medium
1/31/2020	SunTrust Banks	Boost Target	Buy	$141.00	High
1/30/2020	Cowen	Reiterated Rating	Buy	$165.00	High
1/19/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
1/17/2020	Morgan Stanley	Boost Target	Equal Weight	$128.00 ➝ $131.00	Low
1/15/2020	Raymond James	Boost Target	Outperform	$162.00	Low
1/14/2020	William Blair	Reiterated Rating	Buy		Medium
1/13/2020	Wedbush	Reiterated Rating	Outperform		High
12/17/2019	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$170.00 ➝ $128.00	Low
12/6/2019	William Blair	Reiterated Rating	Buy		Low
11/17/2019	Evercore ISI	Reiterated Rating	Buy	$145.00	Low
11/12/2019	SunTrust Banks	Initiated Coverage	Buy	$125.00	Low
10/24/2019	Oppenheimer	Lower Target		$165.00 ➝ $150.00	Low
10/17/2019	Bank of America	Initiated Coverage	Buy		Low
10/16/2019	Cowen	Reiterated Rating	Buy	$165.00	Low
10/11/2019	Morgan Stanley	Lower Target	Overweight	$177.00 ➝ $170.00	Low
9/26/2019	William Blair	Initiated Coverage	Outperform ➝ Outperform	$146.00	High
9/18/2019	Royal Bank of Canada	Reiterated Rating	Buy		Low
9/12/2019	BMO Capital Markets	Initiated Coverage	Outperform	$149.00	Low
9/6/2019	Piper Sandler Companies	Set Target	Buy	$180.00	Low
9/6/2019	Credit Suisse Group	Lower Target	Outperform	$154.00 ➝ $146.00	High
9/3/2019	SVB Leerink	Set Target	Buy	$157.00	Low
8/30/2019	Piper Sandler Companies	Set Target	Buy	$180.00	Low
8/30/2019	Citigroup	Set Target	Buy	$150.00	Low
8/30/2019	Stifel Nicolaus	Reiterated Rating	Hold		Low
8/30/2019	Raymond James	Set Target	Buy	$168.00	Low
8/30/2019	Robert W. Baird	Set Target	Buy	$165.00	Low
8/22/2019	Piper Sandler Companies	Reiterated Rating	Buy		Low
8/21/2019	Morgan Stanley	Set Target	Buy	$177.00	N/A
7/31/2019	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$172.00	Low
7/25/2019	Raymond James	Boost Target	Outperform	$164.00 ➝ $168.00	High
5/23/2019	Citigroup	Lower Target	Buy ➝ Buy	$180.00 ➝ $165.00	Low
5/23/2019	The Goldman Sachs Group	Reiterated Rating	Neutral ➝ Neutral	$142.00	Low
5/22/2019	Wedbush	Initiated Coverage	Outperform ➝ Outperform	$173.00	Medium
4/26/2019	Raymond James	Boost Target	Outperform ➝ Outperform	$161.00 ➝ $164.00	Low

(Data available from 4/23/2019 forward)

News Sentiment Rating

1.28 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/26/2023

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/26/2023

1 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/25/2023

1 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/25/2023

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/24/2024

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/23/2024

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/24/2024

2 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/23/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

No positive mentions tracked during this time.

Very Positive

msn.com
4/2/2024
Alexion’s Voydeya gains FDA approval for extravascular haemolysis
msn.com
3/27/2024
US FDA grants approval for Alexion’s NMOSD treatment

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $182.50

$182.50

50 Day Range

MA: $182.82

$179.45

$186.61

52 Week Range

Now: $182.50

$99.91

$187.45

Volume

10 shs

Average Volume

3,309,941 shs

Market Capitalization

$40.34 billion

P/E Ratio

59.64

Dividend Yield

N/A

Beta

1.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Alexion Pharmaceuticals?: The following Wall Street research analysts have issued reports on Alexion Pharmaceuticals in the last twelve months:
View the latest analyst ratings for ALXN.
What is the current price target for Alexion Pharmaceuticals?: 0 Wall Street analysts have set twelve-month price targets for Alexion Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Alexion Pharmaceuticals in the next year.
View the latest price targets for ALXN.
What is the current consensus analyst rating for Alexion Pharmaceuticals?: Alexion Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ALXN.
What other companies compete with Alexion Pharmaceuticals?: Other companies that are similar to Alexion Pharmaceuticals include Horizon Therapeutics Public, Alnylam Pharmaceuticals, Allergan, BioMarin Pharmaceutical and Royalty Pharma. Learn More about companies similar to Alexion Pharmaceuticals.
How do I contact Alexion Pharmaceuticals' investor relations team?: Alexion Pharmaceuticals' physical mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company's listed phone number is 475-230-2596 and its investor relations email address is [email protected]. The official website for Alexion Pharmaceuticals is www.alexion.com. Learn More about contacing Alexion Pharmaceuticals investor relations.

Alexion Pharmaceuticals - ALXN Stock Price Target and Predictions

Analyst Price Target for ALXN

Current Consensus is N/A

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

1.28 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Alexion Pharmaceuticals?

What is the current price target for Alexion Pharmaceuticals?

What is the current consensus analyst rating for Alexion Pharmaceuticals?

What other companies compete with Alexion Pharmaceuticals?

How do I contact Alexion Pharmaceuticals' investor relations team?